Why Shares of Cassava Sciences Are Dropping Wednesday

Submitted by admin on July 5, 2023 - 7:01pm

Source:

Motley Fool

News Tags:

Headline:

snippet:

Simufilam slowed cognitive decline by 38% compared to a placebo after six months for patients with mild to moderate Alzheimer's disease.
Cassava Sciences has been the target of shareholder lawsuits, short-seller reports, and government inquiries.
The company has enough cash to fund operations into 2025.

Search form